Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) obtained breakthrough therapy designation for its FCN-159 anti-cancer tablets, according to a Monday filing with the Hong Kong bourse.
The drug registration application is for the treatment of three indications of histiocytic neoplasms or abnormal white blood cell proliferation in adults with inoperable or post-operative residual/recurrent NF1-associated PNs and children with Langerhans cell histiocytosis, which causes lesions, the filing said.
Subsidiary Shanghai Fosun Pharmaceutical Industrial Development developed the drug.
Shares rose 2% in Shanghai during Tuesday's afternoon trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。